Stáhnout

Suplementation for CFIDS/ME Patients

Pioneering Work at Breakspear Hospital on Coriolus Suplementation for CFIDS/ME Patients
by Dr. Jean Monro, Breakspear Hospital.
In this case study on the use of Coriolus versicolor in fifteen (15) patients with Chronic Fatigue Syndrome, Dr. Monro measures the increase in Natural Killer Cell (NK) activity over forty five days when Coriolus supplementation is given at 3.0 grams for fifteen (15) days and then decreased to 1.5 grams for thirty (30) days. Results: Coriolus supplementation increased NK cell activity significantly in Chronic Fatigue Syndrome patients.
To contact Dr.Jean Monro at Breakspear Hospital
Tel:44-1442-261-333 / Fax:44-1442-266-388

7.3.2011 |Typ: PDF |Velikost: 560,61 kB |Soubor: Suplementation for CFIDS/ME Patients

Cytokine Th1 to Th2 Shift Can be Reversed by Coriolus versicolor

Cytokine Th1 to Th2 Shift Can be Reversed by Coriolus versicolor Supplementation. Prospective Trial for HPV Control with Coriolus versicolor
By Dr. Jean Monro, Breakspear Hospital.
Presented at the 2nd International Symposium on HPV and Cancer, in Lisbon Portugal on May 26th, 2001.
This prospective trial design outlines the rational for the use of Coriolus versicolor supplementation (3.0 grams per day) to improve the immune system in HPV infected women in order to control the stage of HPV development. Dr. Monro is the first to suggest that Coriolus versicolorsupplementation may reverse a Th1 to Th2 shift in the immune system.
To contact Dr.Jean Monro at Breakspear Hospital
Tel:44-1442-261-333 / Fax:44-1442-266-38

7.3.2011 |Typ: PDF |Velikost: 201,17 kB |Soubor: Cytokine Th1 to Th2 Shift Can be Reversed by Coriolus versicolor

Supplementation in Breast Cancer Patients - Case Study

The Use of Coriolus versicolor Supplementation in Breast Cancer Patients - Case Study
by Dra. Ana Ferro / Paula Boaventura
Presented at the 5th International Symposium on Mushroom Nutrition, University of Westminster, June 14th, 2002.
This abstract outlines the impact of using 4.5 grams per day of Coriolus versicolor supplementation in a breast cancer patient undergoing chemotherapy. The case study outlines the significant impact of Coriolus supplementation on immune parameters and on the quality of life for the patient.
To contact Dra. Ana Ferro / Paula Boaventura
Clinica de Saúde Integral
Rua Constitução, 1959-loja A 4250 / 170 Porto, Portugal
Fax:351-22-832-80-49 / Tel:351-22-832-80-47

7.3.2011 |Typ: PDF |Velikost: 21,46 kB |Soubor: Supplementation in Breast Cancer Patients - Case Study

Supplementation in 30 Cancer Patients

Observational Non-Controlled Study of the Use of Coriolus versicolor Supplementation in 30 Cancer Patients
by Dr. Julian Kenyon
Presented at the 5th International Symposium on Mushroom Nutrition, University of Westminster, June 14th, 2002.
This study of increasing Coriolus versicolor supplementation (4.5 grams per day to 13.0 grams per day over a 90 day period) measures the impact of such supplementation on telomerase activity, interleukin 5, interleukin 12 and Tumour Necrosis Factor Beta over 120 days. Results were a significant decrease in teleomerase and interleukin-12 activity, followed by a significant increase in interleukin-5 activity within 120 days.
To contact Dr. Julian Kenyon (MD MB ChB)
Dove Clinic for Integrated Medicine
97 Harley Street
London W1G 6AG
United Kingdom
Tel:44-207-487-4442
Email: doveclinic@ukonline.co.uk

http://www.doveclinic.com

7.3.2011 |Typ: PDF |Velikost: 54,86 kB |Soubor: Supplementation in 30 Cancer Patients

The Effect of MRL Products on Viability of HepG2 Liver Cancer

The Effect of Aqueous Extracts of MRL Products on Viability of HepG2 Liver Cancer Cells 
by Dr. Chris Newton (Ph.d) Cytogenex
Presented at the 5th International Symposium on Mushroom Nutrition, University of Westminster, June 14th, 2002.
A request was made to CytoGenex to determine whether the MRL nutritional support products, known as Coriolus (BN 03143), Reishi (BN 02194), Cordyceps (BN 03021) and Maitake (BN 03165) had any significant toxicity when tested with a standard toxicity screen. A system has been developed by Cytogenex laboratories based on the liver cell line, HepG2. Toxicity has a number of connotations, but Cytogenex Laboratories takes the term to mean that the test article causes 'no apparent loss of viability of cells used as an assay system'. Viability in this context is taken to mean that cell integrity is maintained. Loss of viability for a cell population is equated with the occurrence of cell death by the mechanism of apoptosis or necrosis. This presentation presents the results of this analysis.
To contact Dr. Chris Newton
CytoGenex Ltd.
121 Westbourne Avenue
Kingson-upon Hull
HU5 3HU
Tel:44-1482-346-381

http://www.cytogenex.com

7.3.2011 |Typ: PDF |Velikost: 66,15 kB |Soubor: The Effect of MRL Products on Viability of HepG2 Liver Cancer

Kontrola kvality

8.3.2011 |Typ: MS PowerPoint |Velikost: 1,35 MB |Soubor: Kontrola kvality


 


TOPlist